MX2015003594A - Agente terapeutico o profilactico para sindrome de lisis tumoral. - Google Patents

Agente terapeutico o profilactico para sindrome de lisis tumoral.

Info

Publication number
MX2015003594A
MX2015003594A MX2015003594A MX2015003594A MX2015003594A MX 2015003594 A MX2015003594 A MX 2015003594A MX 2015003594 A MX2015003594 A MX 2015003594A MX 2015003594 A MX2015003594 A MX 2015003594A MX 2015003594 A MX2015003594 A MX 2015003594A
Authority
MX
Mexico
Prior art keywords
therapeutic
prophylactic agent
tumor lysis
lysis syndrome
present
Prior art date
Application number
MX2015003594A
Other languages
English (en)
Inventor
Takanori Ueda
Takahiro Yamauchi
Mihoko Morita
Hideki Horiuchi
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50544654&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015003594(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MX2015003594A publication Critical patent/MX2015003594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

El propósito de la presente invención es proporcionar un agente terapéutico o profiláctico novedoso para síndrome de lisis tumoral. La presente invención es un agente terapéutico o profiláctico para el síndrome de lisis tumoral, que comprende un compuesto 2-feniltiazol representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo como un ingrediente activo.
MX2015003594A 2012-10-23 2013-10-22 Agente terapeutico o profilactico para sindrome de lisis tumoral. MX2015003594A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012233806 2012-10-23
JP2013002913 2013-01-10
PCT/JP2013/078571 WO2014065275A1 (ja) 2012-10-23 2013-10-22 腫瘍融解症候群の治療薬及び予防薬

Publications (1)

Publication Number Publication Date
MX2015003594A true MX2015003594A (es) 2015-10-09

Family

ID=50544654

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003594A MX2015003594A (es) 2012-10-23 2013-10-22 Agente terapeutico o profilactico para sindrome de lisis tumoral.

Country Status (12)

Country Link
US (2) US20150274680A1 (es)
EP (1) EP2913053A4 (es)
JP (1) JP5907396B2 (es)
KR (1) KR20150073963A (es)
CN (1) CN104981242A (es)
AR (1) AR093093A1 (es)
CA (1) CA2889326A1 (es)
HK (1) HK1216297A1 (es)
MX (1) MX2015003594A (es)
RU (1) RU2627591C2 (es)
TW (1) TWI632911B (es)
WO (1) WO2014065275A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
MX2018001289A (es) 2015-08-03 2018-04-30 Tolero Pharmaceuticals Inc Terapias de combinacion para el tratamiento del cancer.
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CA3042123A1 (en) * 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
CA3111217A1 (en) * 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
MX2021006544A (es) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
WO2020119784A1 (zh) * 2018-12-14 2020-06-18 广州君赫生物科技有限公司 Febuxostat及其衍生物的新应用
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221041B1 (ko) 1990-11-30 1999-09-15 야스이 쇼사꾸 2-아릴티아졸 유도체 및 그의 약제학적 조성물
EP1757610B1 (en) 2004-06-14 2011-06-08 Nippon Chemiphar Co., Ltd. Condensed pyrimidine derivative and xanthine oxidase inhibitor
JPWO2006022375A1 (ja) * 2004-08-27 2008-05-08 アステラス製薬株式会社 ２−フェニルチオフェン誘導体
JP5040656B2 (ja) 2005-10-07 2012-10-03 アステラス製薬株式会社 トリアリールカルボン酸誘導体
KR20160031040A (ko) * 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
CA2755132C (en) 2009-03-31 2018-02-13 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes

Also Published As

Publication number Publication date
TW201429473A (zh) 2014-08-01
JPWO2014065275A1 (ja) 2016-09-08
US20160279106A1 (en) 2016-09-29
WO2014065275A1 (ja) 2014-05-01
RU2015119569A (ru) 2016-12-20
EP2913053A4 (en) 2016-05-25
KR20150073963A (ko) 2015-07-01
CA2889326A1 (en) 2014-05-01
AR093093A1 (es) 2015-05-20
EP2913053A1 (en) 2015-09-02
JP5907396B2 (ja) 2016-04-26
US20150274680A1 (en) 2015-10-01
HK1216297A1 (zh) 2016-11-04
CN104981242A (zh) 2015-10-14
TWI632911B (zh) 2018-08-21
RU2627591C2 (ru) 2017-08-09

Similar Documents

Publication Publication Date Title
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX2016006336A (es) Compuestos pirazolopirimidina.
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12015502839A1 (en) Antiviral compounds
MX2015011245A (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
IN2015MN00404A (es)
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
MY187718A (en) Pharmaceutical formulations
MY183312A (en) Pharmaceutical formulation
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
MX364400B (es) Compuestos de tetraciclina.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MY180006A (en) Azetidinyloxyphenylpyrrolidine compounds
IN2014DN05972A (es)
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
IN2013MU03308A (es)
PH12015501696A1 (en) Prophylactic or therapeutic drug for constipation